29 January 2025
: Case report 
Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Clinical situation which can not be reproduced for ethical reasons
Fatmawati Kamal
1ABCDEF*, Halimatun Radziah Othman2ABCDEF
DOI: 10.12659/AJCR.945579
Am J Case Rep 2025; 26:e945579
Table 1. Initial blood investigation.
| Full blood count | Patient’s result | Reference range | |||
|---|---|---|---|---|---|
| 19.12.21 | 5.1.2022 | 20.1.22 | 24.1.22 | ||
| Anticoagulant | Rivaroxaban | Rivaroxaban + enoxaparin | Enoxaparin | Enoxaparin | |
| White cell count (WBC) (×10/L) | 4.4 | 4.9 | 4.0–10 | ||
| Hemoglobin (g/dL) | 11.6 | 10.9 | 13.0–17.0 | ||
| Mean corpuscular volume (fL) | 86.3 | 86 | 83–101 | ||
| Mean corpuscular hemoglobin (pg) | 28.6 | 29.6 | 27–32 | ||
| Platelet count (×10/L) | 81 | 59 | 150–410 | ||
| Renal profile | |||||
| Urea (mmol/L) | 12.7 | 2.78–8.07 | |||
| Creatinine (μmol/L) | 163 | 62–106 | |||
| Coagulation study | |||||
| Prothrombin time (PT) (sec) | 80.5 | 39.8 | 37.2 | 9.3–10.8 | |
| International normalized ratio (INR) | 8.5 | 4.1 | 3.8 | <1.2 | |
| Activated partial thromboplastin time (aPTT) (secs) | 48.3 | 30.7 | 34.5 | 22.2–31.6 | |